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Abstract: Two pyroglutamyl peptides with anti-colitic activity were 
identified in Japanese rice wine, sake, by oral administration of a small 
dose (0.1-1.0 mg/kg body weight) and in vivo activity-guided 
fractionation. Compounds in sake were fractionated by preparative 
isoelectric focusing followed by preparative reversed phase-liquid 
chromatography. Anti-colitic activity was evaluated using a dextran 
sulfate sodium (DSS)-induced colitis mouse model. The final active 
fraction contained three pyroglutamyl peptides; pyroglutamyl-tyrosine 
(pyroGlu-Tyr), pyroglutamyl-asparaginyl-isoleucine (pyroGlu-Asn-Ile) and 
pyroglutamyl-asparaginyl- 
isoleucyl-asparagyl-asparaginyl-proline (pyroGlu-Asn-Ile-Asp-Asn-Pro). 
Orally administrating artificially synthesized pyroGlu-Tyr (1.0 mg/kg 
body weight) and pyroGlu-Asn-Ile (0.1 and 1.0 mg/kg body weight) 
exhibited a significant protective effect against colitis in mice, 
whereas pyroGlu-Asn-Ile-Asp-Pro showed no significant effect. 
Additionally, administrating pyroGlu-Asn-Ile normalized colitis-induced 
colonic dysbiosis, whereas pyroGlu-Tyr did not. These results suggest 
that identified pyroglutamyl peptides exhibited an anti-colitic activity 











 September 2016 
Dear Professor Rotimi Aluko 
  I am sending herewith the revised manuscript entitled “Identification of pyroglutamyl 
peptides with anti-colitic activity in Japanese rice wine, sake, by oral administration 
in a mouse model” authored by Kiyono et al., to be considered for publication as a 
research paper in Journal of Functional Foods. Ms. Ref. No.:  JFF-D-16-01560R1.  
I revised the manuscript in according to reviewers’ suggestions. 
However, the objective of the present study was to identify anti-colitic peptides by oral 
administration of realistic dose (< 1 mg/kg body weight). I believe you can understand its 
difficulty and impact on following studies. The reviewer suggested more detailed 
characterization of phenotype of disease and molecular mechanism for the peptides. I 
understand its importance. But as written in the list of changes, these results should be 
presented in another article, as it requires development of new methods. 
I believe we provided sufficient data to complete our mission, identification of active 
peptide by oral administration. Now, we are examining response to these peptides by in 
vivo model to identify cells, which respond to the peptides. On the basis of the results, we 









Professor of Division of Applied Biosciences 




List of changes 
 
Comments of Reviewer #1  
In this manuscript by Kiyono et al., entitled "Identification of pyroglutamyl peptides with 
anti-colitic activity in Japanese rise wine, sake, by oral administration in a mouse model," 
Kiyono et al. purified peptides from sake and directly tested them for efficacy in a mouse 
model of dextran sulfate induced colitis. They observed significant improvement in the 
clinical score of DSS treated mice by two pyroglutamyl peptides, pyro-Glu-Tyr and 
polyGlu-Asn-Ile, but not a third pyroGlu-Asn-Ile-Asp-Asn-Pro. 
 
The potential therapeutic application of pyroglutamyl peptides is intriguing and has 
important clinical relevance to ulcerative colitis patients. Screening the peptides directly 
in an in vivo mouse model of colitis is a stringent test for efficacy. Significant protective 
response, particularly for polyGlu-Asn-Ile, is observed. However, a more detailed 
characterization of the mouse disease phenotype with or without treatment with the 
peptides would strengthen the manuscript. Specific comments are given below. 
  
Response for reviewer #1 (general). 
  Thank you for valuable comments. As written in Introduction section, we have 
concentrated all efforts to identify peptides, which can moderate DSS-induced colitis by 
ORAL administration of SMALL dose (< 1mg/kg body weight), in Japanese rice wine. It 
was really challenging. As you also mentioned, identification of active compound by in 
vivo model can provide a stringent result. However, this approach has been hardly used, 
as it has been really difficult to fractionate food compounds enough amounts for animal 
experiment. We solved this problem by developing large-scale peptide fractionator 
(autofocusing). I believe that the identification of anti-colic peptide by oral 
administration of small dose (< 1mg/kg) has great impact on readers of this journal.  To 
make this point clearer, following sentences were added to end of Introduction section; 
“The in vivo activity-guided fractionation can identify really active peptide by oral 
administration compared to the conventional in vitro activity-guided fractionation 
without considering bioavailability. However, it has been difficult to fractionate samples 
to obtain enough amounts of fractions for animal experiment. To solve this problem, the 
present authors have developed large-scale preparative ampholyte free isoelectric 
*Detailed Response to Reviewers
focusing referred to autofocussing (Hashimoto et al., 2005). By using technique, two 
anti-colitic peptides by oral administration of small dose (< 1mg/kg body weight) were 
identified in the present study.” 
  I understand detailed characterization of the mouse disease phenotypes is important and 
valuable information. However, disease index (DI) and criteria included in DI have been 
demonstrated to be good marker to evaluate severity of colitis. Then, to complete the 
present mission, identification of anti-colitic peptide, we believe that DI is enough. 
  In the present study, we identified two anti-colitic peptides by oral administration of 
small dose. Now, we are examining response to these peptides by in vivo model to 
identify cells, which respond to the peptides. On the basis of the results, we will elucidate 
mechanism by in vitro assay. All are challenging. Please understand this step-by-step 
approach.   
To stress importance of this study, following sentences were added to the end of first 
paragraph of Discussion section; “Therefore, these peptides and food containing these 
peptides have important clinical relevance to IBD patients. In addition, identification of 
active peptides allows explore underlying mechanism by using in vitro assay system..” 
 
Specific comments by reviewers’ #1: 
1.  There is little characterization of the DSS-induced colitis beyond the clinical score. 
Histological examination, immune characterization, and/or quantitation of immune 
cytokines and anti-microbial defensins by qPCR would strengthen the manuscript. 
Answer: I agree to this comment. However, in our preliminary experiments, more than 60 
peptides were detected in an acid-extract of small intestine, which contain defensins and 
other antimicrobial peptides. Some peptides shared same sequence, indicating presence 
of heterogeneity among them possibly due to post-translational modifications. Only some 
peptides responded to supplementation of the peptides. Then peptidome analysis based 
two-dimensional LC and mass spectrometry rather than qPCR is now developed. This 
study can be reported in separate article.  
  To explain presence of post-translational modifications of antimicrobial peptides, some 
sentences were added in Discussion section as follows: “In order to identify target cells of 
these peptides in the body and to understand the underlying mechanism, contents of 
inflammatory and anti-microbial peptides responding to supplementation of each peptide 
should be examined. As mammalian antimicrobial peptides are activated by 
post-translational modifications (Balducci et al., 2011), a study on the effects of 
pyroGlu-Tyr, pyroGlu-Asn-Ile, and also pyroGlu-Leu on the proteome of the small 
intestine and colon of the animals with colitis is under progress.” 
 
2. The authors note a difference between the protective effects of the two protective 
peptides, but no interrogation of the mechanisms of these differences is made.  
Additional experimental examination as suggested above may provide some insights into 
the differential effects of the pyroglutamyl peptides.  Testing the pyroglutamyl peptides 
in other experimental colitis models — e.g., other chemical, bacterial, or genetic mouse 
models — may also add mechanistic insight. 
Answer: I agree. Indeed we are examining effect of pyroglutayl peptides on microbiota of 
different animal model. But it is another study.  
 
3. The peptides are only tested at 2 concentrations (0.1 and 1.0 mg/kg).  A more detailed 
dose response, particularly for pENI, the most effective peptide, would be informative. 
Answer: I understand. But this is animal experiment. So many animals should not be used. 
We provided enough data for identification of the peptides with anti-colitic activity by 





1. Editorial corrections would improve the readability of the manuscript, e.g., remove the 
inclusion of experimental details in the abstract, the use of multiple 'etc' in the 
introduction, the beginning of the results section without any introduction as to the 
starting material that is being fractionated.  Also, some of the figures could be combined. 
Answer: The present in vivo activity-guided fractionation is not commonly used due to 
technical difficulty (difficult to prepare enough peptide fractions for animal experiment). 
Then outline of experiments are presented in Abstract. I believe it is important.  
Deleted some etc in Introduction section.  
Starting material is introduced in the Materials and Methods section.  
  
2. Inconsistency in the data presentation (DAI scores or body weights were variably 
reported) led to some confusion and suggestion of data selectivity.  In addition, the only 
significant difference (body weight in mice administered with Fr. III) in Fig. 4 was 
presented in Supplemental Fig. 2.  This data should be move to Fig. 4. 
Answer: Supplemental Fig. 1 and 2 were combined to Figure 2 and 4, respectively. 
 
3. The peptides pyroGlu-Tyr, pyroglutamyl-asparaginyl-isoleucine, and 
pyroglutamyl-asparaginyl-isoleucyl-asparagyl-proline are referred to as pro-Glu-Tyr, 
polyGlu-Asn-Ile, and pyroGlu-Asn-Ile-Asp-Asn-Pro throughout the text, but pEY, pENI, 
and pENIDNP in the figures without providing this abbreviation in the text.  A consistent 
nomenclature would make the manuscript easier to read. 
Answer: Meaning of the one letter abbreviation was described in Figure legend. 
 
4. The differences in nitric oxide production by LPS-treated RAW cells, though 
statistically significant, seem rather minimal (Fig. 7).  This is the only experiment done 
with RAW cells and it is presented in one sentence in the results, without rationale or 
interpretation.  Either more context must be given or these results should be removed. 
The Figure 7 was deleted. 
 
 






 Sake compounds were fractionated by preparative isoelectric focusing and 2 
RP-LC. 3 
 Administration of one fraction attenuated DSS-induced colitis in mice. 4 
 Three pyroglutamyl peptides were identified in the active fraction. 5 
 PyroGlu-Tyr and pyroGlu-Asn-Ile attenuated colitis at 0.1–1.0 mg/kg body 6 
weight. 7 





































































Identification of pyroglutamyl peptides with anti-colitic activity in Japanese rice 1 
wine, sake, by oral administration in a mouse model 2 
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Two pyroglutamyl peptides with anti-colitic activity were identified in Japanese rice wine, 2 
sake, by oral administration of a small dose (0.1–1.0 mg/kg body weight) and in vivo 3 
activity-guided fractionation. Compounds in sake were fractionated by preparative 4 
isoelectric focusing followed by preparative reversed phase-liquid chromatography. 5 
Anti-colitic activity was evaluated using a dextran sulfate sodium (DSS)-induced colitis 6 
mouse model. The final active fraction contained three pyroglutamyl peptides; 7 
pyroglutamyl-tyrosine (pyroGlu-Tyr), pyroglutamyl-asparaginyl-isoleucine 8 
(pyroGlu-Asn-Ile) and pyroglutamyl-asparaginyl- 9 
isoleucyl-asparagyl-asparaginyl-proline (pyroGlu-Asn-Ile-Asp-Asn-Pro). Orally 10 
administrating artificially synthesized pyroGlu-Tyr (1.0 mg/kg body weight) and 11 
pyroGlu-Asn-Ile (0.1 and 1.0 mg/kg body weight) exhibited a significant protective effect 12 
against colitis in mice, whereas pyroGlu-Asn-Ile-Asp-Pro showed no significant effect. 13 
Additionally, administrating pyroGlu-Asn-Ile normalized colitis-induced colonic 14 
dysbiosis, whereas pyroGlu-Tyr did not. These results suggest that identified 15 
pyroglutamyl peptides exhibited an anti-colitic activity via different mechanisms. 16 
 17 





































































1. Introduction 1 
  Inflammatory bowel disease (IBD) is a chronic disorder of the gastrointestinal tract and 2 
includes ulcerative colitis and Crohn’s disease (Podolsky, 2002). Patients suffering from 3 
IBD show symptoms characterized by diarrhea, bloody stools, and weight loss. IBD is 4 
generally treated with a combination of anti-inflammatory and immunomodulatory drugs. 5 
In some cases, these therapies exert limited efficacy and have a risk of adverse effects 6 
(Bernstein, 2015). Several efforts have been focused towards the discovery of natural 7 
compounds from foods that display protection against IBD. Some plant extracts rich in 8 
phytochemicals (Zorrilla et al., 2014; Jia et al., 2014; Cazarin et al., 2015; Zielinska et al., 9 
2015) and some proteins (Lee et al., 2009a, 2009b; Kobayashi et al., 2015) have been 10 
demonstrated to moderate IBD in animal models. In those studies, decrease and/or down 11 
regulation of pro-inflammatory cytokines and enzymes involved in inflammation such as 12 
inducible nitric oxide synthase, cyclooxygenase-2 have been demonstrated. Based on 13 
these findings, anti-inflammatory activity in colon has been suggested to be the 14 
mechanism for moderation of IBD by such food compounds. The IBD symptoms can be 15 
alleviated by pre- and pro-biotics through improvement of colonic microbiota and 16 
metabolites of microbiota such as short chain fatty acids (Osman et al., 2008; Damaskos 17 
& Kolios, 2008; Hijova & Soltesova, 2013), which can consequently suppress colonic 18 
inflammation. Then apparent anti-inflammatory response by ingestion of these foods 19 




































































of host cells in colon. The identification of active compound in the food, which can 1 
ameliorate IBD by oral administration, is crucial to elucidate the underlying mechanism 2 
of anti-colitic activity. The response of specific cells, including host and exogenous cells, 3 
can be elucidated by using compounds isolated from food. It has been demonstrated that 4 
food compounds with some beneficial in vitro activity such as the anti-oxidant activity, 5 
also exert anti-colitic activity (Osman et al., 2008; Larrosa et al., 2009; Yoda et al., 2014). 6 
However, in most studies considerably higher doses than normally present in foods were 7 
needed to exert beneficial effects against colitis in animal models. Therefore, the 8 
beneficial effects of the plant extract could not solely be attributed to the suggested 9 
compounds and their in vitro activities. Similarly, some amino acids, derived from dietary 10 
proteins, also improve the symptoms of IBD; however, the effective doses are higher than 11 
the content in the protein. There is a possibility that specific peptides, which could be 12 
derived from proteins, might be responsible for suppression of IBD, however, there are 13 
few data indicating such active peptide in food. Recently, we found that 14 
pyroglutamyl-leucine (pyroGlu-Leu), which was identified in wheat gluten enzymatic 15 
hydrolysate as hepatoprotective peptide by oral administration (Sato et al., 2013),
 
also 16 
attenuates dextran sulfate sodium (DSS)-induced colitis and normalizes the colonic 17 
dysbiosis in mice upon oral administration at 0.1 mg/kg body weight (Wada et al., 2013). 18 
Pyroglutamyl peptide, wherein the pyroglutamic acid residue is generated from amino 19 




































































Suzuki et al., 1999) and fermented foods (Kaneko et al., 2011; Kiyono et al., 2013). We 1 
previously reported that Japanese rice wine, sake, a fermented alcohol beverage made of 2 
water and rice inoculated with Aspergillus oryzae and Saccharomyces cerevisiae, 3 
contains 12–15 mg/L of pyroGlu-Leu, and eighteen other short chain pyroglutamyl 4 
peptides (Kiyono et al., 2013). In the context of IBD, the objective of the present study 5 
was to identify other pyroglutamyl peptides with protective effect against colitis present 6 
in sake by oral administration in sma ll dose. The in vivo activity-guided fractionation can 7 
identify really active peptide by oral administration compared to the conventional in vitro 8 
activity-guided fractionation without considering bioavailability. However, it has been 9 
difficult to fractionate samples to obtain enough amounts of fractions for animal 10 
experiment. To solve this problem, the present authors have developed large-scale 11 
preparative ampholyte free isoelectric focusing referred to autofocussing (Hashimoto et 12 
al., 2005). By using technique, two anti-colitic peptides by oral administration of small 13 




2. Materials and Methods 16 
2.1. Samples. 17 
  Bottled sake (15% alcohol content) made from rice polished to 60%, was commercially 18 
obtained from Shotoku Brewery (Kyoto, Japan). Sake was concentrated (5-fold) by a 19 




































































2.2. Reagents. 1 
  Lipopolysaccharide (LPS) from Escherichia coli, O111 B4 was obtained from Sigma 2 
(Saint Louis, MO). Fetal bovine serum (FBS) and Dulbecco's modified Eagle's medium 3 
(DMEM) were obtained from JR Scientific (Woodland, CA) and Thermo Fisher 4 
Scientific (Waltham, MA), respectively. Dextran sulfate sodium (DSS; average molecular 5 
weight, 8,000) was purchased from Seikagaku (Tokyo, Japan). Pyrococcus furiosus 6 
pyroglutamate aminopeptidase was purchased from Takara Bio (Otsu, Japan). 7 
Acetonitrile (HPLC grade), trifluoroacetic acid (TFA), and phenyl isothiocyanate (PITC) 8 
were purchased from Wako Chemicals (Osaka, Japan). Triethylamine (TEA) was 9 
purchased from Thermo Fisher Scientific. L-pyroglutamic acid was purchased from 10 
Nacalai Tesque (Kyoto, Japan). 9-fluorenylmethoxycarbonyl (Fmoc)-Tyr(tBu)-Wang 11 
resin, Fmoc-Ile-Wang resin, H-Pro-2-chlorotritylchloride resin, and Fmoc-amino acids 12 
for peptide synthesis were purchased from HiPep Laboratories (Kyoto, Japan). Other 13 
reagents used were of analytical or higher grade. 14 
2.3. DSS-induced colitis in mice.  15 
  Animal experiments were conducted according to a previously described procedure 16 
(Wada et al., 2013). Seven-week-old male C57BL/6 mice were purchased from Shimizu 17 
Laboratory Supplies (Kyoto, Japan). The mice (n= 6 or 7) were housed in a room under 18 
controlled conditions of 18–24°C, 40–70% relative humidity, and a 12 h light/dark cycle. 19 




































































drinking water during a one-week acclimatization period. All animals were treated and 1 
cared for in accordance with the National Institutes of Health’s Guide for the Care and 2 
Use of Laboratory Animals, 8th Edition. All experimental procedures were approved by 3 
the Animal Care Committee of Kyoto Prefectural University of Medicine (M23–37, 4 
M24–25, Kyoto, Japan). 5 
  Acute colitis was induced by oral administration of 2.5 or 3.0% (w/v) DSS dissolved in 6 
drinking water for 7 days. The working concentration of DSS (2.5% or 3.0%) was 7 
determined by preliminary experiments by using the same batch of animals to induce an 8 
identical grade of inflammation (more than disease activity index score 2) as described in 9 
a previous study (Wada et al., 2013). Mice were allowed free access to drinking water 10 
either containing DSS (DSS +) or without DSS (DSS –). Samples were dissolved in 11 
distilled water and administered by gavage in aliquots of 200 μL once a day during the 12 
entire induction period. The vehicle group of mice received an identical amount of 13 
distilled water. The body weight of each mouse was measured on days 0, 3, 5, and 7. Mice 14 
were sacrificed on day 7 and the entire colon was removed. Immediately after colon 15 
resection, the colon length was measured. 16 
  For the identification of active fraction, the severity of colitis was evaluated by a 17 
disease activity index (DAI) score as previously reported (Wada et al., 2013). The DAI 18 
score was determined by scoring of weight loss, stool consistency and bleeding as 19 




































































2.4. Fractionation of compounds in sake by preparative isoelectric focusing.  1 
  For animal experiments, the concentrated compounds in sake were fractionated by 2 
preparative isoelectric focusing based on the amphoteric nature of the sample according 3 
to a previously described method (Hashimoto et al., 2005) with slight modifications (Sato 4 
et al., 2013). This method has been referred to as autofocusing. An autofocusing 5 
apparatus with 12 compartments (75 mm in length × 80 mm in width × 85 mm in height 6 
for each compartment), separated by a thin agarose gel layer was prepared. Phosphoric 7 
acid at 0.03 M concentration and 0.1 M sodium hydroxide were loaded in the 8 
compartments at either ends of the tank, which were used as anode and cathode, 9 
respectively. Ten compartments in the center of the tank were used as sample 10 
compartments and were numbered from the anode side (No. 1) to the cathode side (No. 11 
10). Sample compartments number 8 and 9 were each filled with 500 mL of the 5-fold 12 
sake concentrate. The other sample compartments were filled with deionized water. 13 
Autofocusing was performed at constant voltage mode at 500 V for 24 h. Following this, 14 
all fractions were collected and their pH adjusted to 7.0 by addition of 1 M HCl or sodium 15 
hydroxide, and used for subsequent experiments. 16 
2.5. Fractionation of compounds by preparative reversed phase-liquid 17 
chromatography.  18 
  The fraction obtained after autofocusing, which attenuated DSS-induced colitis in mice, 19 




































































chromatography (RP-LC). The RP-LC system consisted of a column (160 × 15 mm, 1 
Millipore, Billerica, MA) packed with YFLC Gel ODS (50 μm particle size, 120 Å pore 2 
size, Yamazen, Osaka, Japan), a pump (FL600A, Yamazen), a gradient controller 3 
(Gradicon III AC-5900, Atto, Tokyo, Japan), and a gradient mixer (AC-5905, Atto). The 4 
column was equilibrated with 10 mM HCl at a flow rate of 10 mL/min. Following this, 80 5 
mL of the autofocusing fraction, diluted to 3.0 mg peptide/mL for animal experiments, 6 
was loaded to the column using the pump. Elution was performed using a binary linear 7 
gradient consisting of 10 mM HCl (solvent A) and 10 mM HCl containing 60% (v/v) 8 
acetonitrile (solvent B). Gradient profile was 0% B for 1 min followed by 0–100% B over 9 
20 min and 100% B for 2 min. Fractions were collected every 0.5 min. Elution was 10 
monitored by absorbance at 214, 230, and 254 nm using UV/Vis spectrometer (DU640, 11 
Beckman Coulter, Brea, CA). 12 
2.6. Identification of pyroglutamyl peptides.  13 
  Identification of pyroglutamyl peptides was performed by using methods described 14 
previously (Kiyono et al, 2013) with slight modifications. About 4 mL aliquots of the 15 
preparative RP-LC fraction, which attenuated DSS-induced colitis in mice, was dried 16 
under vacuum and dissolved in 400 μL of 0.1% (v/v) TFA containing 30% acetonitrile. 17 
This sample was clarified by passing through a spin column (15 × 7 mm i.d., 5 μm pore 18 
size, Ultrafree-MC, Millipore) packed with Sephadex G-25 fine grade (GE Healthcare, 19 




































































eluted from the spin column by centrifugation at 7,000 rpm for 1 min after which the spin 1 
column was washed with 50 μL of the same solvent, and the effluents were combined 2 
(450 μL of total volume). A 200-μL aliquot of the clarified sample was loaded onto a size 3 
exclusion chromatography (SEC) column (Superdex Peptide 10/30 GL, GE Healthcare), 4 
pre-equilibrated with 0.1% TFA containing 30% acetonitrile at a flow rate of 0.5 mL/min. 5 
Fractions (21–45 in number) were collected at 1 min interval for 20–45 min. This 6 
procedure was performed in duplicate. 7 
  The SEC fractions 31–45 above were dried under vacuum, dissolved in 200 μL of 8 
distilled water, and subjected to solid phase extraction using a strong cation exchange 9 
resin (AG50W-x8, hydrogen form, 100–200 mesh, Bio-Rad Laboratories, Hercules, CA) 10 
to separate the pyroglutamyl peptides from peptides bearing amino groups. The sample 11 
(200 μL) was loaded onto the spin column packed with the resin, which was 12 
pre-equilibrated with 10 mM HCl containing 50% (v/v) methanol, and eluted by 13 
centrifugation at 5,000 x g for 1 min. The columns were washed twice with 100 μL of 14 
50% methanol. Unabsorbed effluents were combined and dried under vacuum, and then 15 
dissolved in 200 μL of distilled water. Unabsorbed samples (80 μL) were injected to a 16 
reversed phase-high performance liquid chromatography (RP-HPLC) column (Inertsil 17 
ODS-3, 250 × 4.6 mm, 5 μm, GL Science, Tokyo, Japan) pre-equilibrated with 0.1% 18 
formic acid at a flow rate of 1.0 mL/min. Elution was performed using a binary linear 19 




































































acetonitrile (solvent B). The gradient profile was as follows: 0–30% B from 0–30 min; 1 
30–100% B from 30–35 min; 100% B from 35–40 min; 100–0% B from 40–40.1 min; 0% 2 
B from 40.1–50 min. Column temperature was maintained at 45°C. Elution was 3 
monitored at 214 nm and peaks were collected. Two sets of sample aliquots (100 μL) 4 
were transferred to 1.5-mL centrifuge tubes and dried under vacuum. One set was used 5 
for pyroglutamate aminopeptidase digestion and another set was used as blank. One 6 
hundred microliter of 50 mM sodium phosphate buffer, pH 7.0, containing 10 mM 7 
dithiothreitol and 1 mM ethylendiaminetetraacetic acid was added to the blank tubes. 8 
Eighty microliter of the same buffer and 20 μL of pyroglutamate aminopeptidase solution 9 
(0.4 mU/20 μL of the same buffer) were added to the tubes used for the digestion. The 10 
enzymatic reaction was carried out at 60°C for 1 h. The reaction was terminated by drying 11 
under vacuum. The amino groups liberated upon digestion from the pyroglutamyl peptide 12 
underwent a reaction with PITC and the resulting phenyl thiocarbamyl (PTC) derivatives 13 
were resolved by RP-HPLC as previously described (Kiyono et al., 2013). Peaks 14 
appearing exclusively in the enzyme digests were collected and dried under vacuum, 15 
following which a ‘re-drying solution’ (20 μL) consisting of methanol, water, and TEA 16 
(7:1:2) was added and the contents were re-dried under vacuum to remove ammonia. The 17 
residual contents were dissolved in 30% methanol and applied to an automatic peptide 18 
sequencer operating based on Edman degradation (PPSQ-21, Shimadzu, Kyoto, Japan). 19 






































































  Aliquots of the RP-HPLC fractions without pyroglutamate aminopeptidase treatment 1 
were subjected to direct infusion electrospray ionization-tandem mass spectrometry 2 
(ESI-MS/MS) analysis using 3200 QTRAP System (AB SCIEX, Framingham, MA). 3 
2.7. Synthesis of pyroglutamyl peptides.  4 
  Pyroglutamyl-tyrosine (pyroGlu-Tyr), pyroglutamyl-asparaginyl-isoleucine 5 
(pyroGlu-Asn-Ile), and pyroglutamyl-asparaginyl-isoleucyl-asparagyl-asparaginyl- 6 
proline (pyroGlu-Asn-Ile-Asp-Asn-Pro) were synthesized by Fmoc solid phase synthesis 7 
using an automatic peptide synthesizer (PSSM-8, Shimadzu) according to the supplier’s 8 
protocols. The synthesized pyroglutamyl peptides were cleaved from the resin using TFA 9 
and dried under vacuum. These peptides were then purified using RP-HPLC (Cosmosil 10 
5C18-MS-II, 250 × 10 mm, 5 μm, Nacalai Tesque) using an acetonitrile/10 mM HCl 11 
solvent system.  12 
2.8. Amino acid analysis.  13 
  Peptide content was determined by amino acid analysis after HCl hydrolysis. For this 14 
purpose, samples were hydrolyzed using 6 M HCl vapor at 150°C as described previously 15 
(Bidlingmeyer, Cohen & Tarvin, 1984). The amino acids were reacted with PITC and the 16 
resulting PTC amino acids were resolved using the same conditions used for isolation of 17 
PTC-peptides in pyroglutamate aminopeptidase digest as described previously (Kiyono 18 
et al., 2013).  19 




































































  Samples were diluted with distilled water to result in absorbance values within the 1 
standard curve range. Concentrated sulfuric acid (150 μL) and 10% (w/v) phenol (15 μL) 2 
were added to samples (30 μL) in 1.5 mL centrifuge tubes and incubated for 10 min. The 3 
tubes were then vortexed and incubated further for 30 min. Reaction mixtures were 4 
transferred to a 96 well plate and absorbance was monitored at 490 nm. The sugar 5 
contents of samples are presented as glucose equivalents. 6 
2.10. Detection of pyroGlu-Leu.  7 
  PyroGlu-Leu in preparative RP-LC fractions was detected by LC-MS/MS analysis as 8 
described previously (Wada et al., 2013). 9 
2.11. Microbiota analysis.  10 
  DNA was extracted from mice feces by using a QIAamp DNA Stool Mini Kit (Qiagen, 11 
Venlo, Netherlands). Analysis of fecal bacterial flora in the extracted DNA was 12 
outsourced to Primary Cell, Division of Cosmo Bio (Sapporo, Japan). The population of 13 
phylum Bacteroidetes and Firmicutes in mice feces were evaluated as the ratio of each 14 
phylum to all bacteria by genomic DNA coding 16S rRNA. The DNA amplification was 15 
carried out by real-time polymerase chain reaction (RT-PCR). HDA1-GC 16 
(5’CGCCCGGGGCGCGCCCCGGGCGGGGCGGGGGCACGGGGGGACTCCTACG17 
GGAGGCAGCAGT3’) and HDA2 (5’GTATTACCGCGGCTGCTGGCAC3’) were 18 
used for detection of all bacteria (Tannock et al., 2000). Bact934F 19 




































































(5’AGCTGACGACAACCATGCAG3’) were used for detection of Bacteroidetes. 1 
Firm934F (5’GGAGYATGTGGTTTAATTCGAAGCA3’) and Firm1060R 2 
(5’AGCTGACGACAACCATGCAC3’) were used for detection of Firmicutes (Guo et al., 3 
2008). Real-time PCR was performed using a LightCycler 480 (Roche Applied Science, 4 
Mannheim, Germany) according to the SYBR Green I Master Protocol.  5 
2.12. Statistical analysis.  6 
  The body weight change, colon length, and DAI scores in DSS-induced colitis mice are 7 
presented as mean ± standard error. The ratio of two microorganisms 8 
(Firmicutes/Bacteroidetes) in the feces of mice is also presented as mean ± standard error. 9 
Data were subjected to one-way ANOVA with Dunnett’s multiple comparison of means 10 
test. Differences of p < 0.05 were considered significant. Statistical analysis was 11 
performed using Ekuseru-Toukei 2010 Version1.11 (Social Survey Research Information, 12 
Tokyo, Japan). 13 
 14 
3. Results 15 
3.1. Fractionation by autofocusing.  16 
  The pH of the ten fractions (Fr.) produced by autofocusing of the sake sample was 17 
about 3.0 between Fr. 1–8 then rose sharply in Fr. 9 and 10 to pH 9.0 and 13.0, 18 
respectively (Figure 1A). Approximately 80% of total peptides were recovered in Fr. 8 19 




































































Peptides present in Fr. 3–8 consisted of higher levels of acidic amino acids (such as 1 
glutamic acid) after HCl hydrolysis, and peptides in Fr. 10 consisted of higher levels of 2 
basic amino acids (such as arginine and lysine) compared with the other fractions (Figure 3 
1C). This charge-based separation of amino acids indicated successful fractionation of 4 
peptides contained in sake based on their isoelectric points. A relatively high sugar 5 
content (~ 24%) was recovered in the acidic fractions, particularly Fr. 6 and 7 (Figure 1D). 6 
All autofocusing fractions were mixed with ethanol at end concentrations of 75% (v/v) in 7 
order to remove agarose, which was derived from the separator of autofocusing. Based on 8 
the results of autofocusing, Fr. 1–5 and 6–7 obtained after autofocusing were pooled into 9 
two different fractions and used further for animal experiments. Fr. 8, 9, and 10 were used 10 
for animal experiments without pooling. The samples were further concentrated by a 11 
rotary evaporator to remove ethanol and then diluted with distilled water to give 3.0 12 
mg/mL peptide (total amino acids) and administered to the mice with DSS-induced colitis 13 
at 30 mg/kg body weight a day. 14 
  The induction of colitis was confirmed by a significant increase in DAI score observed 15 
after treatment with DSS (DSS +), as compared to the mice that did not receive DSS (DSS 16 
-) (Figure 2A). Only the mice receiving autofocusing Fr. 8 showed a significant decrease 17 
in DAI score compared to the vehicle group (DSS +). However, the crude sake 18 
concentrate, before undergoing autofocusing, exerted no significant decrease in the DAI 19 




































































(Figure 2B), and there was no significant difference in colon length among all groups 1 
(Figure 2C). Based on the above data, Fr. 8 was selected for a further fractionation 2 
treatment to identify active compounds. 3 
3.2. Fractionation by RP-LC.  4 
  Fraction 8 (3.0 mg/mL peptide) was subjected to further fractionation by RP-LC. 5 
Following the elution of non-absorbed compounds from the RP-LC column, the absorbed 6 
compounds were eluted by increasing acetonitrile concentrations (Figure 3A). Free 7 
amino acids and sugars were mostly eluted in the non-absorbed fraction (Figure 3A and 8 
B). The peptide content could be estimated by subtracting free amino acids from total 9 
amino acids in HCl hydrolysate. Peptides were eluted in both the non-absorbed and the 10 
absorbed fractions. A strong UV absorbance peak was observed at 20–21 min (Figure 3C). 11 
Thus, four fractions were collected and labeled as follows: Fr. I (0–14 min), Fr. II 12 
(14–17.5 min), Fr. III (17.5–20 min) and Fr. IV (20–31 min). These fractions were 13 
freeze-dried to remove acetonitrile and dissolved into 80 mL of distilled water, which 14 
were further used for animal experiments. 15 
  Although statically insignificant (p > 0.05), the smallest DAI score was observed in 16 
RP-LC Fr. III group (p = 0.08) among the mice receiving Fr. I-IV compared to the vehicle 17 
group (DSS +) (Figure 4A). In addition, administration of Fr. III significantly averted 18 




































































significant difference in colon length among all groups (Figure 4C). Based on these 1 
results, Fr. III was used for further experiments.   2 
3.3. Identification of pyroglutamyl peptides with protective effect against 3 
DSS-induced colitis in RP-LC Fr. III.  4 
  Peptides contained in Fr. III were initially resolved by SEC. Approximately 75% of the 5 
total peptides eluted between 30–36 min corresponding to Fr. 31–36 (data not shown). 6 
Pyroglutamyl peptides in Fr. 31–36 were separated from peptides bearing amino groups 7 
by solid phase extraction and then resolved by RP-HPLC. The major peaks obtained after 8 
RP-HPLC; marked as a, b, and c; were collected (Figure 5A) and. aliquots of the collected 9 
fractions were digested with pyroglutamate aminopeptidase. The digested and 10 
non-digested samples were allowed to react with PITC and the resulting PTC derivatives 11 
were resolved by a second RP-HPLC separation. Peaks a’, b’, and c’ appeared only in 12 
case of enzyme digests (Figure 5B). These PTC derivatives were identified by Edman 13 
degradation as follows; peak a’, tyrosine; peak b’, asparaginyl-isoleucine and peak c’, 14 
asparaginyl-isoleucyl-asparagyl-asparaginyl-proline. This fact indicated that peaks a, b, 15 
and c in Figure 5A consisted of pyroglutamyl-tyrosine (pyroGlu-Tyr), 16 





































































proline (pyroGlu-Asn-Ile-Asp-Asn-Pro), respectively. ESI-MS and MS/MS analyses of 1 
peaks a–c also confirmed the presence of pyroGlu-Tyr, pyroGlu-Asn-Ile, and 2 
pyroGlu-Asn-Ile-Asp-Asn-Pro, respectively (Supplemental Fig 1–3). 3 
  Three identified pyroglutamyl peptides were chemically synthesized and administered 4 
to the mice with DSS-induced colitis. Although statistically insignificant, (p > 0.05), the 5 
administration of these pyroglutamyl peptides showed a tendency towards reduced body 6 
weight loss compared to the vehicle group (DSS +) (Figure 6A). The pyroGlu-Asn-Ile 7 
group (1.0 mg/kg body weight) showed the smallest body weight loss. Administration of 8 
pyroGlu-Tyr and pyroGlu-Asn-Ile, at 1.0 mg/kg body weight, significantly reduced colon 9 
shortening (p < 0.05 and p < 0.01, respectively) (Figure 6B). Additionally, 10 
pyroGlu-Asn-Ile significantly decreased DAI score compared to the vehicle group (DSS 11 
+) in a dose dependent manner (Figure 6C). However, pyroGlu-Asn-Ile-Asp-Asn-Pro did 12 
not significantly attenuate colon shortening and DAI score increasing of DSS-induced 13 
colitis mice. 14 
3.4. Effects of pyroglutamyl peptides on colonic microbiota.  15 
  Without administration of pyroglutamyl peptides, DSS treatment resulted in an increase 16 
in the population of colonic Firmicutes and decrese in that of Bacteroidetes. Thus, a 17 
significantly increased ratio between the colonic populations of Firmicutes to 18 
Bacteroidetes by DSS treatment was observed  (Figure 6D). The ratio significantly 19 




































































pyroGlu-Asn-Ile. On the other hand, pyroGlu-Tyr did not significantly affect the ratio of 1 
Firmicutes to Bacteroidetes. 2 
  3 
4. Discussion 4 
  It is known that some crude plant extracts have been demonstrated to have anti-colitic 5 
activity in animal models (Zorrilla et al., 2014; Jia et al., 2014; Cazarin et al., 2015; 6 
Zielinska et al., 2015). Some compounds with demonstrated in vitro anti-oxidant, 7 
anti-inflammatory and other similar beneficial activities have been selected as candidate 8 
anti-colitic compounds. However, relatively large dose of these compounds are necessary 9 
for improving colitis in animal model possibly due to low bioavailability and rapid 10 
metabolism of these compounds (Larrosa et al., 2009; Shigeshiro, et al., 2013; Sun et al., 11 
2016). To address this problem, we used in vivo activity-guided fractionation rather than 12 
in vitro activity-guided fractionation for identification of anti-colitic peptides in sake. The 13 
present in vivo activity-guided fractionation revealed that pyroGlu-Tyr and 14 
pyroGlu-Asn-Ile contained in sake attenuated DSS-induced colitis in mice upon oral 15 
administration in relatively low concentrations (1.0 mg/kg body weight for pyroGlu-Tyr, 16 
and 0.1 and 1.0 mg/kg body weight for pyroGlu-Asn-Ile). This protective effect exerted 17 
by the pyroglutamyl peptides was better at lower concentrations when compared to the 18 
dose dependence displayed by other natural compounds reported previously. Therefore, 19 




































































IBD patients. In addition, identification of active peptides allows explore underlying 1 
mechanism by using in vitro assay system. 2 
   A previous study reported that pyroGlu-Leu, the major pyroglutamyl peptide in sake 3 
(12–15 mg/L) (Kiyono et al., 2013) can attenuate DSS-induced colitis upon 4 
administration at 0.1 mg/kg body weight, while doses higher than 0.5 mg/kg body weight 5 
and lower than 0.01 mg/kg body weight do not exert any protective effects in the same 6 
animal model (Wada et al., 2013). The preset in vivo activity-guided fractionation did not 7 
detect pyroGlu-Leu as active compound. LC-MS/MS analysis revealed that pyroGlu-Leu 8 
was recovered in RP-LC Fr. IV (data not shown). However, as shown in Figure 4, DAI 9 
score of the mice receiving RP-LC Fr. IV was higher than that of the mice receiving 10 
RP-LC Fr. III possibly due to the higher pyroGlu-Leu content (0.31 mg/kg body weight) 11 
than optimized dosage (Wada et al., 2013). 12 
   A previous study demonstrated that in comparison to the mice without colitis, 13 
DSS-mediated colitis induced mice showed a higher ratio of Firmicutes to Bacteroidetes, 14 
the two major phyla of mice colonic microbiota, and administration of pyroGlu-Leu in 15 
mice with colitis normalized their colonic dysbiosis (Wada et al, 2013). This study 16 
confirms the previous finding related to changes in colonic microbiota in mice with 17 
DSS-induced colitis. Additionally, this study revealed that administration of 18 
pyroGlu-Asn-Ile also normalized the colonic dysbiosis in DSS-induced colitis mice, 19 




































































colonic myeloperoxidase activity was decreased by administration of pyroGlu-Tyr 1 
compared to that of the vehicle group (DSS +), indicating that colonic inflammation was 2 
suppressed by administration of pyroGlu-Tyr (Supplemental Fig. 4). These results 3 
indicate that attenuation of colitis does not always result in normalization of colonic 4 
microbiota. However, it has been indicated that intestinal dysbiosis plays significant role 5 
in inflammatory bowel disease (Sartor & Mazmanian, 2012). Therefore, normalization of 6 
colonic dysbiosis by administration of pyroGlu-Asn-Ile can potentially attenuate colitis.  7 
   In addition, to pyroGlu-Leu, pyroGlu-Tyr and pyroGlu-Asn-Ile have potential 8 
anti-inflammatory activity (Figure 7), however, the target cells responding to each 9 
pyroglutamyl peptide remains to be solved. In order to identify target cells of these 10 
peptides in the body and to understand the underlying mechanism, contents of 11 
inflammatory and anti-microbial peptides responding to supplementation of each peptide 12 
should be examined. As mammalian antimicrobial peptides are activated by 13 
post-translational modifications (Balducci et al., 2011), a study on the effects of 14 
pyroGlu-Tyr, pyroGlu-Asn-Ile, and also pyroGlu-Leu on the proteome of the small 15 
intestine and colon of the animals with colitis is under progress.   16 
 The present study clearly demonstrates that sake contains at least three pyroglutamyl 17 
peptides (pyroGlu-Leu, pyroGly-Tyr, and pyroGlu-Asn-Ile), which can attenuate 18 
DSS-induced colitis in mice at doses of 0.1-1.0 mg/kg body weight. However, crude sake 19 




































































such as lactic acid and succinic acid, which are abundantly present in sake (Tadenuma, 1 
1966), may induce diarrhea and worsen the symptom of colitis (Tsukahara & Ushida, 2 
2002). Thus sake contains both components with beneficial and adverse effects on colitis 3 
and optimizing the contents of these compounds could produce functional beverages 4 
against colitis. Currently, studies on producing anti-colitic beverages by optimizing 5 
fermentation conditions for sake are in progress.   6 
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Figure captions 1 
Figure 1. Fractionation of sake concentrate by ampholyte-free preparative isoelectric 2 
focusing (autofocusing). pH value (A), total peptides content (total constituent amino 3 
acids after HCl hydrolysis) (B), ratio of the basic, neutral, and acidic amino acids to the 4 
total peptide contents (C), and sugar content as glucose equivalent (D) of each 5 
autofocusing fraction are shown. 6 
 7 
Figure 2. Effect of administrating of autofocusing fractions of sake on DAI scores (A), 8 
body weight change (B), and colon length (C) in mice with DSS-induced colitis. Values 9 
are presented as mean ± standard error. DSS – and DSS + represents the mice, which were 10 
allowed free access to DSS free drinking water and water containing DSS, respectively. 11 
Sample doses were adjusted to 30 mg /kg body weight for peptide (total amino 12 
acids)/content. ** represents p < 0.01, when compared to the vehicle group (DSS +) by 13 
Dunnett’s test. 14 
 15 
Figure 3. Re-fractionation of compounds in autofocusing Fr. 8 by preparative RP-LC. 16 
Arrows indicate initiation of an acetonitrile gradient. Free amino acids content (white 17 
circle) and total constituent amino acids content obtained after HCl hydrolysis (black 18 
circle) (A), sugar content as glucose equivalent (B), and absorbance in the UV range (C) 19 





































































Figure 4. Effect of preparative reversed-phase liquid chromatography (RP-LC) Fr. I–IV 2 
on DAI scores (A), body weight change (B), and colon length (C) in mice with 3 
DSS-induced colitis. DSS – and DSS + represents the mice that were allowed free access 4 
to normal water and water containing DSS, respectively. Values are presented as mean ± 5 
standard error. ** represents p < 0.01, when compared to the vehicle group (DSS +) by 6 
Dunnett’s test. 7 
 8 
Figure 5. Identification of pyroglutamyl peptides in RP-LC Fr. III. Size exclusion 9 
chromatography (SEC) Fr. 31–36 of the RP-LC Fr. III were further subjected to 10 
RP-HPLC (A). Compounds in peaks a, b, and c in panel A were digested with 11 
pyroglutamate aminopeptidase and derivatized with phenyl isothiocyanate. The resultant 12 
phenyl thiocarbamyl-amino acids/peptides were resolved by second RP-HPLC (B). +, 13 
sample digested with pyroglutamate aminopeptidase; −, non-digested samples. Peaks 14 
marked a’, b’, and c’ in panel B yielded phenyl thiohydantoin-amino acids/peptides upon 15 
Edman degradation. Peaks marked with asterisks did not liberate amino acids or peptides 16 
after pyroglutamate aminopeptidase digestion (A) and Edman degradation (B). 17 
 18 
Figure 6. Effects of pyroGlu-Tyr (pEY), pyroGlu-Asn-Ile (pENI), and 19 




































































change (A), colon length (B), DAI score (C), and ratio of the colonic population of 1 
Firmicutes to Bacteroidetes (D) are shown. DSS – and DSS + represents the mice that 2 
were allowed free access to normal drinking water and water containing DSS, 3 
respectively. V represents the vehicle group. Values are presented as mean ± standard 4 
error. * and ** represent p < 0.05, and < 0.01, respectively, when compared to the vehicle 5 
group (DSS +) by Dunnett’s test. 6 
 7 









0 None Normal Negative 
1 1–5 Mild loose Light 
2 5–10 Loose Mild 
3 10–20 Mild bleeding Severe 
4 >20 diarrhea Entire 
*
DAI = (Combined scores of weight loss, stool consistency and bleeding)/3. 
**Normal, formed pellets; Loose, pasty stools that do not stick to the anus; diarrhea, 
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Supplementary figure 1. Electrospray ionization-mass spectrometry (ESI-MS) 
spectrum of the peak a, pyroGlu-Tyr, in Figure 5A. 
 
Supplemental Figure





Supplementary figure 2. ESI-MS spectrum of the peak b, pyroGlu-Asn-Ile, in 
Figure 5A (upper) and ESI-tandem mass spectrometry (ESI-MS/MS) spectrum of 













Supplementary figure 3. ESI-MS spectrum of peak c, 
pyroGlu-Asn-Ile-Asp-Asn-Pro, in Figure 5A (upper) and ESI-MS/MS spectrum of 




Supplementary figure 4. Myeloperoxidase activity of the colonic extract of mice 
with colitis. Mice were received water (vehicle) or pyroGlu-Tyr. 
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